The association between periodontal disease and cardiovascular disease — first noted in observational studies in the 1990s — has been strengthened by two decades of epidemiological, mechanistic, and interventional research into one of medicine's most compelling oral-systemic disease connections. The biological plausibility is no longer in question: multiple independent mechanisms link chronic gingival and periodontal infection to atherosclerosis, myocardial infarction, stroke, and heart failure. What remains debated is whether treating periodontal disease can reduce cardiovascular events — a question that requires large randomized trials not yet completed at adequate scale.
Epidemiological Evidence
A 2019 systematic review and meta-analysis in Cardiovascular Research (European Society of Cardiology official journal) synthesized data from 81 studies involving over 2.3 million participants: individuals with periodontitis had 24% higher risk of coronary artery disease, 17% higher risk of stroke, and 34% higher risk of atrial fibrillation than those without periodontal disease. These associations persisted after adjustment for major confounders including smoking, diabetes, and socioeconomic status. Dose-response relationships — more severe periodontitis correlating with higher cardiovascular risk — further support causal inference.
Biological Mechanisms
Three mechanistic pathways are well-characterized: (1) Direct bacterial dissemination: bacteremia occurs regularly during chewing, tooth brushing, and dental procedures in periodontitis patients. Oral bacteria including P. gingivalis have been identified in atheromatous plaques by PCR and culture, and can adhere to and invade vascular endothelial cells, promoting foam cell formation. (2) Systemic inflammation: periodontal inflammation elevates systemic CRP, fibrinogen, IL-6, and TNF-α — the same cytokine profile seen in cardiovascular risk. Successful periodontal treatment reduces CRP by an average of 0.5 mg/L (a clinically meaningful reduction comparable to statin therapy effects on CRP). (3) Molecular mimicry: antibodies against periodontal bacteria cross-react with cardiac myosin and HSP60 — potentially contributing to autoimmune-mediated cardiac inflammation.
The ADVOCATE Trial and Interventional Evidence
The ADVOCATE pilot trial demonstrated that intensive periodontal treatment significantly reduced brachial flow-mediated dilation (a biomarker of endothelial function and subclinical CVD) over 6 months versus control. The larger PEARL trial (Periodontitis and Its Relation to Coronary Artery Disease) is ongoing. While definitive cardiovascular outcome data from periodontal intervention RCTs is awaited, current clinical consensus — supported by AHA/ADA joint scientific statements — recommends that cardiovascular patients be informed of the periodontal-CVD association and that coordination between cardiologists and periodontists be incorporated into high-risk patient management. Dental facilities providing periodontal care should stock comprehensive periodontal instruments and wound care supplies for post-surgical management.
